GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (LTS:0MGB) » Definitions » Cyclically Adjusted PB Ratio

Genmab A/S (LTS:0MGB) Cyclically Adjusted PB Ratio : 8.67 (As of Jun. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Genmab A/S Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Genmab A/S's current share price is kr1949.00. Genmab A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was kr224.84. Genmab A/S's Cyclically Adjusted PB Ratio for today is 8.67.

The historical rank and industry rank for Genmab A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0MGB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 8.55   Med: 23.3   Max: 34.31
Current: 8.6

During the past years, Genmab A/S's highest Cyclically Adjusted PB Ratio was 34.31. The lowest was 8.55. And the median was 23.30.

LTS:0MGB's Cyclically Adjusted PB Ratio is ranked worse than
88.05% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs LTS:0MGB: 8.60

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab A/S's adjusted book value per share data for the three months ended in Mar. 2024 was kr498.868. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr224.84 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted PB Ratio Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.77 29.31 22.44 17.77 10.22

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.57 13.80 12.53 10.22 9.25

Competitive Comparison of Genmab A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted PB Ratio falls into.



Genmab A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genmab A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1949.00/224.84
=8.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Genmab A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=498.868/118.4000*118.4000
=498.868

Current CPI (Mar. 2024) = 118.4000.

Genmab A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 30.878 99.700 36.670
201409 34.029 99.700 40.412
201412 35.686 99.400 42.507
201503 44.521 100.200 52.608
201506 47.169 100.300 55.681
201509 51.232 100.200 60.538
201512 58.570 99.800 69.486
201603 59.005 100.200 69.722
201606 62.650 100.600 73.735
201609 65.407 100.200 77.287
201612 80.111 100.300 94.568
201703 82.563 101.200 96.595
201706 89.143 101.200 104.294
201709 89.528 101.800 104.127
201712 102.679 101.300 120.012
201803 106.623 101.700 124.131
201806 111.998 102.300 129.624
201809 115.461 102.400 133.502
201812 130.691 102.100 151.555
201903 132.163 102.900 152.071
201906 134.683 102.900 154.971
201909 192.564 102.900 221.570
201912 216.421 102.900 249.021
202003 221.347 103.300 253.703
202006 274.168 103.200 314.549
202009 282.807 103.500 323.520
202012 292.309 103.400 334.714
202103 307.337 104.300 348.885
202106 308.622 105.000 348.008
202109 325.529 105.800 364.297
202112 337.744 106.600 375.130
202203 345.620 109.900 372.351
202206 372.331 113.600 388.063
202209 404.941 116.400 411.899
202212 417.337 115.900 426.339
202303 416.881 117.300 420.790
202306 440.462 116.400 448.030
202309 476.335 117.400 480.392
202312 483.848 116.700 490.896
202403 498.868 118.400 498.868

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab A/S  (LTS:0MGB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genmab A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (LTS:0MGB) Business Description

Industry
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (LTS:0MGB) Headlines

No Headlines